Inference of personalized drug targets via network propagation

Pacific Symposium on Biocomputing

Volumn , Issue , 2016, Pages 156-167

  Shnaps, Ortal ^a   Perry, Eyal ^a   Silverbush, Dana ^a   Sharan, Roded ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

COSMOLOGY; DRUG THERAPY; FORECASTING;

COMPUTATIONAL STRATEGY; DRUG TARGETS; EXPRESSION DATA; IN-SILICO; IN-VITRO; PATIENT SPECIFIC; POTENTIAL DRUG TARGETS; PROTEIN-PROTEIN INTERACTION NETWORKS;

PROTEINS;

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN;

ALGORITHM; BIOLOGY; COMPUTER SIMULATION; DRUG DATABASE; DRUG DEVELOPMENT; DRUG EFFECTS; GENE REGULATORY NETWORK; GENETICS; HUMAN; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MUTATION; PERSONALIZED MEDICINE; PROCEDURES; PROTEIN PROTEIN INTERACTION; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; FMS-LIKE TYROSINE KINASE 3; GENE REGULATORY NETWORKS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PRECISION MEDICINE; PROTEIN INTERACTION MAPS;

EID: 85012224964     PISSN: 23356928     EISSN: 23356936     Source Type: Journal    
DOI: 10.1142/9789814749411_0015     Document Type: Conference Paper

References (33)

1. P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, and N. Rosen, “RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF,” Nature, vol. 464, no. 7287, pp. 427–430, Mar. 2010.
2. P. M. Rothwell, “Can overall results of clinical trials be applied to all patients?,” The Lancet, vol. 345, no. 8965, pp. 1616–1619, Jun. 1995.
3. M. Hofree, J. P. Shen, H. Carter, A. Gross, and T. Ideker, “Network-based stratification of tumor mutations,” Nat. Methods, vol. 10, no. 11, pp. 1108–1115, Nov. 2013.
4. M. Niepel, M. Hafner, E. A. Pace, M. Chung, D. H. Chai, L. Zhou, B. Schoeberl, and P. K. Sorger, “Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines,” Sci. Signal., vol. 6, no. 294, Sep. 2013.
5. J. A. DiMasi, R. W. Hansen, and H. G. Grabowski, “The price of innovation: new estimates of drug development costs,” J. Health Econ., vol. 22, no. 2, pp. 151–185, Mar. 2003.
6. A. Gottlieb, G. Y. Stein, E. Ruppin, and R. Sharan, “PREDICT: a method for inferring novel drug indications with application to personalized medicine,” Mol. Syst. Biol., vol. 7, p. 496, Jun. 2011.
7. J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, S. J. Haggarty, P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander, and T. R. Golub, “The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease,” Science, vol. 313, no. 5795, pp. 1929–1935, Sep. 2006.
8. G. Hu and P. Agarwal, “Human Disease-Drug Network Based on Genomic Expression Profiles,” PLoS ONE, vol. 4, no. 8, Aug. 2009.
9. A. P. Chiang and A. J. Butte, “SYSTEMATIC EVALUATION OF DRUG-DISEASE RELATIONSHIPS TO IDENTIFY LEADS FOR NOVEL DRUG USES,” Clin. Pharmacol. Ther., vol. 86, no. 5, pp. 507–510, Nov. 2009.
10. P. P. Zarrinkar, R. N. Gunawardane, M. D. Cramer, M. F. Gardner, D. Brigham, B. Belli, M. W. Karaman, K. W. Pratz, G. Pallares, Q. Chao, K. G. Sprankle, H. K. Patel, M. Levis, R. C. Armstrong, J. James, and S. S. Bhagwat, “AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML),” Blood, vol. 114, no. 14, pp. 2984-2992, Oct. 2009.
11. R. Chuang, B. A. Hall, D. Benque, B. Cook, S. Ishtiaq, N. Piterman, A. Taylor, M. Vardi, S. Koschmieder, B. Gottgens, and J. Fisher, “Drug Target Optimization in Chronic Myeloid Leukemia Using Innovative Computational Platform,” Sci. Rep., vol. 5, Feb. 2015.
12. M. F. Ciaccio, V. C. Chen, R. B. Jones, and N. Bagheri, “The DIONESUS algorithm provides scalable and accurate reconstruction of dynamic phosphoproteomic networks to reveal new drug targets,” Integr. Biol. Quant. Biosci. Nano Macro, vol. 7, no. 7, pp. 776–791, Jul. 2015.
13. S. Fatumo, K. Plaimas, J.-P. Mallm, G. Schramm, E. Adebiyi, M. Oswald, R. Eils, and R. König, “Estimating novel potential drug targets of Plasmodium falciparum by analysing the metabolic network of knock-out strains in silico,” Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis., vol. 9, no. 3, pp. 351–358, May 2009.
14. B. Papp, C. Pál, and L. D. Hurst, “Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast,” Nature, vol. 429, no. 6992, pp. 661–664, Jun. 2004.
15. P. Csermely, V. Ágoston, and S. Pongor, “The efficiency of multi-target drugs: the network approach might help drug design,” Trends Pharmacol. Sci., vol. 26, no. 4, pp. 178–182, Apr. 2005.
16. O. Vanunu, O. Magger, E. Ruppin, T. Shlomi, and R. Sharan, “Associating genes and protein complexes with disease via network propagation,” PLoS Comput. Biol., vol. 6, no. 1, p. e1000641, Jan. 2010.
17. G. Marcucci, T. Haferlach, and H. Döhner, “Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications,” J. Clin. Oncol., p. JCO.2010.30.2554, Jan. 2011.
18. H. Wang, H. Hu, Q. Zhang, Y. Yang, Y. Li, Y. Hu, X. Ruan, Y. Yang, Z. Zhang, C. Shu, J. Yan, E. K. Wakeland, Q. Li, S. Hu, and X. Fang, “Dynamic transcriptomes of human myeloid leukemia cells,” Genomics, vol. 102, no. 4, pp. 250–256, Oct. 2013.
19. “Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia,” N. Engl. J. Med., vol. 368, no. 22, pp. 2059–2074, May 2013.
20. S. A. Forbes, N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. Menzies, J. W. Teague, P. J. Campbell, M. R. Stratton, and P. A. Futreal, “COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer,” Nucleic Acids Res., vol. 39, no. Database issue, pp. D945–D950, Jan. 2011.
21. M. Kanehisa and S. Goto, “KEGG: Kyoto Encyclopedia of Genes and Genomes,” Nucleic Acids Res., vol. 28, no. 1, pp. 27–30, Jan. 2000.
22. M. Kanehisa, S. Goto, Y. Sato, M. Kawashima, M. Furumichi, and M. Tanabe, “Data, information, knowledge and principle: back to metabolism in KEGG,” Nucleic Acids Res., vol. 42, no. Database issue, pp. D199–205, Jan. 2014.
23. B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz, and K. W. Kinzler, “Cancer Genome Landscapes,” Science, vol. 339, no. 6127, pp. 1546–1558, Mar. 2013.
24. C. Scholl, D. G. Gilliland, and S. Fröhling, “Deregulation of signaling pathways in acute myeloid leukemia,” Semin. Oncol., vol. 35, no. 4, pp. 336–345, Aug. 2008.
25. M. Ruffalo, M. Koyuturk, and R. Sharan, “Network-Based Integration of Disparate Omic Data To Identify ‘Silent Players’ in Cancer,” submitted, 2015.
26. C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon, K. Banco, C. Mak, V. Neveu, Y. Djoumbou, R. Eisner, A. C. Guo, and D. S. Wishart, “DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs,” Nucleic Acids Res., vol. 39, no. Database issue, pp. D1035–1041, Jan. 2011.
27. V. Law, C. Knox, Y. Djoumbou, T. Jewison, A. C. Guo, Y. Liu, A. Maciejewski, D. Arndt, M. Wilson, V. Neveu, A. Tang, G. Gabriel, C. Ly, S. Adamjee, Z. T. Dame, B. Han, Y. Zhou, and D. S. Wishart, “DrugBank 4.0: shedding new light on drug metabolism,” Nucleic Acids Res., p. gkt1068, Nov. 2013.
28. D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, and J. Woolsey, “DrugBank: a comprehensive resource for in silico drug discovery and exploration,” Nucleic Acids Res., vol. 34, no. Database issue, pp. D668–672, Jan. 2006.
29. D. S. Wishart, C. Knox, A. C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. Gautam, and M. Hassanali, “DrugBank: a knowledgebase for drugs, drug actions and drug targets,” Nucleic Acids Res., vol. 36, no. Database issue, pp. D901–906, Jan. 2008.
30. L. Jin, Y. Tabe, H. Lu, G. Borthakur, T. Miida, H. Kantarjian, M. Andreeff, and M. Konopleva, “Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment,” Cancer Lett., vol. 329, no. 1, pp. 45–58, Feb. 2013.
31. C. Nishioka, T. Ikezoe, J. Yang, and A. Yokoyama, “Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4Ebinding protein 1 and down-regulation of McL-1,” Apoptosis Int. J. Program. Cell Death, vol. 15, no. 7, pp. 795–804, Jul. 2010.
32. E. K. Keeton, K. McEachern, K. S. Dillman, S. Palakurthi, Y. Cao, M. R. Grondine, S. Kaur, S. Wang, Y. Chen, A. Wu, M. Shen, F. D. Gibbons, M. L. Lamb, X. Zheng, R. M. Stone, D. J. Deangelo, L. C. Platanias, L. A. Dakin, H. Chen, P. D. Lyne, and D. Huszar, “AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia,” Blood, vol. 123, no. 6, pp. 905–913, Feb. 2014.
33. M. H. Schaefer, J.-F. Fontaine, A. Vinayagam, P. Porras, E. E. Wanker, and M. A. Andrade-Navarro, “HIPPIE: Integrating Protein Interaction Networks with Experiment Based Quality Scores,” PLoS ONE, vol. 7, no. 2, p. e31826, Feb. 2012.